The Allstate Corporation (NYSE: ALL) — The Hard-Market Winner, Now Spending Its Peak Margins to Buy Back the Growth It Lost

⚡ Claude’s Take

The author’s own independent opinion and general information only — not investment advice. The analytical body (Sections 1–15) below is deliberately position-free; this opening block is the single place a view is expressed.

Verdict: HOLD / own-for-the-quality / accumulate-on-weakness toward the high-$180s. Not a short. Fair-value zone ≈ $200–245 (≈1.65–1.95× ~$115 common book; ≈11–13× a normalized ~$16–19 EPS). Current price ~$221. Conviction: medium.

Allstate is a genuinely good underwriter caught at a flattering moment. The headline numbers shout “cheap” — a 4.8× trailing GAAP P/E sits in the 1.6th percentile of its own decade — but that number is a trap, stitched together from $1.6B of one-time divestiture gains, an $1.8B prior-year reserve release, and an auto book running at an 89.5% underlying combined ratio against a mid-90s target. This is peak underwriting profitability, and management says so out loud: they intend to give margin back to re-accelerate the policy growth they bled away from 2022–2024 while fixing prices. The honest tells are P/B in the 77th percentile (~1.85×) and P/S in the 99.7th percentile — the market is paying up on sales that have been inflated 38% in four years by rate, not units. So the real debate isn’t “is it cheap”; it’s “what does this franchise earn at mid-cycle, and will trading margin for share create value or just hand the underwriting profit back to customers and Progressive.”

My read: the franchise quality is real (top-quartile fixed-income returns, a 5–10yr auto combined ratio of 94–95 and homeowners of 92–93.5, a fortress ~10% debt/cap balance sheet, and a 71% reduction in share count since 1995), the price is full but not absurd (composite valuation only in the 59th own-history percentile — the least stretched of the big-four P&C names vs. PGR/TRV/CB), and the tape is a low-beta (0.66 market / 0.31 raw), high-Sharpe quality/low-vol/income grind near all-time highs — a quality compounder at a fair price, not a falling knife and not a value bargain. You own it for ~13% capital returns and book-value compounding, not for multiple expansion. Framing: quality-at-a-fair-price / late-cycle. Tag: “They fixed the margins; now they’re spending them to buy back the growth they lost.” Flips bullish if PIF growth re-accelerates to 4–5%+ with the combined ratio holding at/below target — proof the margin-for-growth trade compounds value and earns a higher multiple. Flips bearish if loss-cost inflation re-accelerates (or post-cut rates prove inadequate) and the combined ratio drifts back toward/above 96–100 while units stall — that is a 25–35% earnings air-pocket the multiple does not yet discount.

📈 Stock Price Action — Five-Year Event Map

Over five years Allstate round-tripped from a split/dividend-adjusted low near $90 (Feb 2021) to an all-time high of ~$226 (19 May 2026), and trades at ~$221 today — roughly 2.5× off the 2021 low and ~2% below the high, with a 52-week range of ~$185–$226. The striking feature is what didn’t happen: the stock barely flinched during the 2022–2023 auto-underwriting catastrophe (it actually rose), then ground steadily higher as the rate-driven margin recovery materialized. This has been a low-drawdown re-rating (3-yr max drawdown only ~14%), not a boom-bust.

Cycle narrative. (1) 2021 was the calm before the storm — frequency was recovering but the inflation that would wreck 2022 was just starting. (2) In 2022 Allstate posted a −$1.3B loss as the auto combined ratio hit 110, yet the stock rose: insurance is defensive, and investors chose to look through the underwriting trough to the rate increases being filed. (3) 2023 was a holding pattern — results stayed poor (cat losses spiked to $5.6B) and the stock chopped sideways. (4) 2024 is where the thesis paid off: cumulative auto rate of 30%+ earned in, the PL combined ratio fell to 94.3, investment income hit records, and the stock re-rated ~40%. (5) 2025 added peak underwriting margins plus $1.6B of gains from exiting Health & Benefits. (6) 2026 carried to an all-time high before a KBW downgrade to Market Perform and a heavy May catastrophe month ($289M) took ~2% off the top. The price move is a Fact; the attributed causes are Interpretation, cross-referenced to earnings prints, 8-Ks, and the news feed.

1. Executive Summary

The Allstate Corporation is the third-largest U.S. personal-lines property-casualty insurer (behind State Farm and Progressive), a ~$54B-market-cap franchise built on auto and homeowners insurance distributed through Allstate-brand agents, the National General independent-agent platform, direct/digital channels, and a growing fee-based Protection Services arm (SquareTrade product-protection plans, roadside, Arity telematics, identity protection). FY2025 consolidated revenue was $67.7B with net income to common of $10.2B.

The investment question is entirely about where in the cycle these economics sit. Allstate just completed one of the sharpest underwriting round-trips in its history: a property-liability combined ratio that blew out to 106.6 in 2022 (auto alone at 110.1) as used-car prices, parts, labor and medical severity outran inadequate rates, producing GAAP losses in 2022 and 2023 — followed by a violent, rate-driven recovery to a 94.3 combined ratio in 2024 and 85.2 in 2025, the best in five years. Return on equity traced the same arc: −2.7% (2022) → −0.6% (2023) → 8.8% (2024) → 17.6% (2025). The 2025 result is additionally flattered by $1.6B of pre-tax gains on the divestiture of the Health & Benefits businesses and an $1.8B favorable prior-year reserve release. First-quarter 2026 underlying combined ratios — auto at 89.5% against a stated mid-90s target — confirm the book is earning above mid-cycle.

This sets up the central tension. On trailing GAAP earnings the stock looks absurdly cheap (P/E in the 1.6th percentile of its own history), but that is an artifact of peak-plus-one-time earnings. On the metrics that survive the distortion — price-to-book in the 77th percentile (~1.85×) and price-to-sales in the 99.7th percentile — the market is paying a full price. Management has been explicit that it now intends to convert that margin cushion into policy growth (“to the extent we can drive growth and give up some margin, that works to improve shareholders’ valuation multiples”), pivoting from the defensive rate-and-shrink posture of 2022–2024 back to share gains (total policies in force +2.5% in Q1-26 after years of attrition). That pivot is the whole thesis: executed well, it lifts the multiple and grows book value; executed poorly, it simply returns the hard-market windfall to policyholders and to Progressive/GEICO, which have out-grown Allstate in auto for a decade.

The franchise quality underwriting that debate is genuine and gives the stock a real floor: a 5–10-year auto combined ratio of 94–95 and homeowners of 92–93.5; a top-quartile, conservatively positioned $83B investment portfolio (71% fixed income) now compounding net investment income at ~10%+ as it reinvests at higher yields; a fortress balance sheet (debt/capital ~10%, A-rated, $7.5B of deployable holding-company assets); and a 30-year record of relentless capital return (shares outstanding down 71% since 1995, a $4.0B buyback newly authorized in February 2026 equal to ~7% of the company). Capital allocation is above-average and incentives are reasonably aligned (the long-term plan pays on a net-income ROE metric plus relative TSR), though governance carries the usual mature-mega-cap demerits: a combined Chair/President/CEO in his 19th year, ~1.55% insider ownership, and no open-market insider buying.

Net: a high-quality, well-financed underwriter at a fair-to-full price, near all-time highs, on peak-of-cycle margins that management plans to partially spend on growth. This is a “own the compounding and the capital return, don’t pay up for the multiple” situation — the body that follows takes no position; the labeled Claude’s Take above does.

2. Business Overview

Allstate sells protection — predominantly personal auto and homeowners insurance in the United States and Canada — and increasingly fee-based product protection. Following a 2025 reorganization, the company reports four segments: Allstate Protection (the core P&C underwriter), Protection Services (fee businesses), Run-off Property-Liability (legacy A&E and discontinued lines), and Corporate and Other. The former Allstate Health & Benefits segment was divested in 2025 (see Section 8).

Allstate Protection (~88% of revenue; the engine). FY2025 segment revenue was $59.7B, of which $57.7B was insurance premiums earned, split:

Auto is ~66% of P&C premium and homeowners ~27%; the two are sold heavily as a bundle. Distribution spans four channels under multiple brands — Allstate (captive exclusive agents plus direct/call-center/web), National General (the independent-agent platform acquired in 2021, also non-standard auto), Direct Auto, and Answer Financial (an insurance brokerage that also places competitors’ products). Allstate-brand auto average premium reached $850 in 2025 and homeowners $2,263 (+12% YoY) after the rate cycle.

Protection Services (~5% of revenue but ~82% of total policy count; the growth optionality). FY2025 revenue $3.55B, comprising:

• Allstate Protection Plans (SquareTrade) — extended product-protection plans for phones, electronics, appliances and furniture sold through major retailers; revenue $2.16B (+15% YoY) and the largest piece. Management notes revenue has grown ~8× since the 2017 acquisition and the business earned ~$175M adjusted net income over the trailing twelve months.
• Dealer Services (vehicle service contracts/GAP), Roadside, Arity (a telematics/data business that powers usage-based pricing and also sells data externally), and Allstate Identity Protection.

This is genuinely recurring, capital-light, fee-based revenue — a deliberate strategic hedge to broaden “protection provided per customer” beyond the rate-regulated insurance core.

How it makes money. Two engines: (1) underwriting profit — premiums less losses and expenses, measured by the combined ratio (below 100 = profit); and (2) net investment income — the return on the ~$83B float and capital portfolio ($3.45B in 2025, +11.5%). Revenue recurs through annual policy renewals at high retention; Protection Services adds multi-year contract revenue. The model is cyclical because loss costs (inflation, catastrophes, litigation) move faster than rate filings can be approved, producing the kind of multi-year margin swing visible above.

Verdict: A scaled, multi-channel, multi-brand personal-lines franchise with a growing fee-based adjacency. The core is a regulated, cyclical commodity (auto/home insurance) where Allstate is a strong but not dominant operator; the durable economics come from scale, brand, claims/pricing sophistication, and float — examined next.

3. Industry Dynamics

Structure. U.S. personal auto and homeowners insurance is a large (~$400B+ direct premium), mature, fragmented-at-the-edges but consolidated-at-the-top oligopoly. The top five auto carriers (State Farm, Progressive, GEICO/Berkshire, Allstate, USAA) write the majority of the market; Allstate holds roughly a high-single-digit/~10% auto share and is a top-two homeowners writer. It is a scale industry with regulated pricing — a combination that, per the Greenwald framework, can support genuine economies of scale (fixed costs of brand, claims infrastructure, data/analytics, and reinsurance buying spread over a huge premium base) but caps the upside because state regulators must approve rates and explicitly aim to prevent “excess” profit.

Profit pool and the cycle. This is a textbook Marathon capital-cycle industry. When rates are adequate and catastrophe/loss experience is benign, the whole industry earns attractive returns, which (a) attracts capital and aggressive pricing (Progressive leaning in, new capacity, insurtech) and (b) invites regulatory rate rollbacks — both of which erode margins. When loss costs spike (as in 2021–2023), the industry under-earns or loses money, capital exits or retrenches, carriers shrink and raise rates, and margins eventually over-correct to the upside (2024–2025). Allstate today sits at the over-correction phase: industry auto margins are at a cyclical high after the 2022–2023 repricing, which is precisely why rate increases have slowed to roughly neutral and competitors (and Allstate itself) are pivoting back to growth. The capital-cycle warning is that high returns are self-correcting — the mid-90s auto combined-ratio target (not the current 89.5%) is the honest through-cycle anchor.

Competitive intensity. Auto is intensely price-competitive and increasingly a direct-response/advertising arms race — Progressive and GEICO spend billions on advertising and have structurally lower expense ratios via direct distribution. Allstate’s historical weakness is exactly here: a higher-cost captive-agent model that ceded share to direct players for fifteen years. Its multi-year “Transformative Growth” program is the response — cutting expense ratios (PL expense ratio down from 24.5 in 2021 to 21.4 in 2025), building Allstate-brand direct capability, simplifying products (the “ASC” affordable/simple/connected auto and home products now in 40+ states), and using telematics (Arity) and AI to price and serve more cheaply. Homeowners is less competitive and more attractive — fewer top-five carriers want the catastrophe-exposed risk, which is why Allstate frames home as an “underappreciated growth asset” where it can profitably gain share at 83% of the U.S. market.

Regulation. The binding constraint. State insurance departments approve rates and can “reduce, freeze, or set rates at levels that do not correspond with underlying costs.” The pain states are well known: California (where Allstate paused growth and is awaiting reforms to the intervenor process and faster rate approvals), New York (where Allstate sees major upside if no-fault/“fender-bender litigation” reform passes), and Florida (where Allstate has stopped writing new homeowners/condo business). This regulatory friction is double-edged: it suppresses returns in problem states but also forms a barrier to entry/exit that protects incumbents and slows the capital cycle.

Verdict: a structurally average-to-good industry — better than a pure commodity because of scale economies, float, brand, regulatory barriers and high renewal retention, but worse than a true franchise because pricing is regulated, the product is undifferentiated at point of sale, switching costs are modest, and returns are aggressively mean-reverted by both the capital cycle and rate regulators. Allstate is a strong operator inside a cyclical, regulated oligopoly.

4. Competitive Position

The moat, named. Allstate’s advantage is economies of scale plus claims/pricing intangibles, concentrated in two places: (1) the homeowners book, where it profitably gains share at 83% of the country while several top-five rivals retrench from catastrophe risk; and (2) claims and pricing sophistication — a centralized reserving function separate from pricing actuaries, “billions of price points per state,” Arity telematics on “50 million cars… every 15 seconds,” and the reinsurance-buying scale to cap its 1-in-100 PML at only ~$3.1B net on an $83B balance sheet. The financial proof that this is real: a 5- and 10-year auto combined ratio of 94–95 and homeowners of 92–93.5, both better than industry average over time, and the ability to raise rates 30%+ through 2022–2024 without losing the franchise (auto PIF troughed and is now growing again, +2.3% in 2025).

Where the moat is weaker. In auto, Allstate is not the low-cost producer — that is GEICO and Progressive, whose direct models carry structurally lower expense ratios. For fifteen years Allstate’s captive-agent cost structure meant it had to choose between margin and share, and it generally chose margin, ceding auto share to Progressive. The entire Transformative Growth program is an admission that the cost-and-distribution disadvantage was real; it is narrowing (expense ratio down ~3 points) but not eliminated. Switching costs in auto are low (shopping is a 15-minute online exercise), brand matters but is not decisive against a 15% price gap, and the bundling advantage (auto + home together lowers acquisition cost and churn) is shared by State Farm and others.

Head-to-head. Against Progressive (covered separately): Progressive is the better auto machine — faster-growing, lower-cost, ~40% comprehensive ROE at the cycle peak, trading at 3–4× book on its own richest-ever multiple. Allstate is the value-er, lower-multiple, higher-yield, more homeowners-weighted, lower-growth alternative — a different animal. Against Travelers and Chubb (more commercial/specialty-weighted), Allstate is the purer personal-lines play, more exposed to auto-rate cyclicality and homeowners catastrophe but also to the personal-lines hard-market recovery. The factor model confirms the kinship: Allstate’s closest statistical twin is Hartford (HIG), then TRV/CINF/CB — the personal-and-commercial-lines cohort, not the specialty insurers.

Pressure-testing “network effects” and durability. There are no network effects here. The durable question is whether the data/AI advantage compounds: management is betting that its “connected technology ecosystem” and agentic-AI build (“ALLIE”) let it lower expenses and price more granularly than rivals burdened by legacy systems. That is plausible but unproven against Progressive, the acknowledged data/pricing leader. If a “moat” claim can’t be tied to a financial outcome that would deteriorate without it, it isn’t a moat — here the homeowners share gains and the through-cycle sub-95 auto combined ratio are such outcomes, so the moat is real but narrow and partly cost-disadvantaged in its largest line.

Verdict: a durable but second-tier moat — genuine scale, claims/pricing intangibles and a real homeowners edge, offset by a structural auto cost/distribution gap versus the direct leaders. Allstate is the strong #3/#4 in a scale oligopoly, not the franchise king.

5. Growth History and Forward Opportunities

History — rate, not units. Revenue grew from $41.7B (2020) to $67.7B (2025), a ~10% CAGR, but the composition matters: the bulk came from price, not policy growth. Through the 2022–2024 repricing, Allstate deliberately shrank policies in force in unprofitable states and raised auto rates ~30% cumulatively — auto PIF fell from 25.3M (2023) to 24.9M (2024) before recovering to 25.5M (2025). Allstate-brand auto average premium rose from $757 (2023) to $850 (2025); homeowners from $1,812 to $2,263. This is low-quality, defensive “growth” in the sense that it was loss-cost recovery, not franchise expansion — exactly what you would expect from a carrier digging out of an underwriting hole.

The inflection. That phase is ending. In Q1-26, with rate increases slowed to roughly neutral (23 states cut, 16 raised, 10 did both), total policies in force grew 2.5% and Allstate gained auto share in 29 states representing 57% of premium and homeowners share in 41 states. New business is at “historically high levels” across all channels. The strategic pivot is explicit: having restored margins, Allstate now wants unit growth, and is prepared to trade some of the current excess margin (auto underlying CR 89.5 vs mid-90s target) to get it.

Forward opportunities (ranked by credibility):

1. Homeowners share gains — the most credible. A profitable, less-competitive line where Allstate grows at 83% of the market while rivals retrench. Average premium +12% in 2025 keeping pace with loss costs.
2. Auto re-acceleration via lower expenses/AI — Transformative Growth’s expense-ratio reductions create room to price more competitively and still hit target margins. Credible but contested by Progressive’s superior cost position.
3. Regulatory unlocks — New York no-fault reform (Allstate has a large NYC share and calls it a “giant growth market” if reform passes) and California intervenor reform. Real optionality, but outside Allstate’s control and slow.
4. Protection Services — SquareTrade/Allstate Protection Plans growing low-teens, capital-light, fee-based. A genuine, if small (~5% of revenue), high-quality growth vector.
5. Net investment income — a quieter tailwind: the $83B portfolio is reinvesting at higher new-money yields (NII +11.5% in 2025, +9.8% in Q1-26), and management has been actively adding equity exposure (doubled to ~12% of the portfolio).

Verdict: historically low-quality (rate-driven, unit-shrinking) growth that is just now inflecting toward higher-quality unit growth. The forward opportunity is real — homeowners, Protection Services, NII, regulatory optionality — but the auto unit-growth ambition runs directly into Progressive’s cost advantage and the risk that “buying” growth with margin simply normalizes returns. Quality of forward growth: improving, but unproven.

6. Financial Quality

Underwriting — the cyclical core. The combined-ratio history is the single most important table in this memo:

The story is unambiguous: a 2022–2023 auto-led underwriting collapse, then a violent recovery to an 85.2 combined ratio in 2025. But 2025 is below the through-cycle target on three counts: the auto underlying combined ratio (89.5% in Q1-26) is running ~5 points better than the mid-90s target; cat losses ($5.0B, 8.6 points) were not extreme; and a large favorable prior-year reserve release (3.1 points, $1.8B) boosted the headline. Normalize for all three and the sustainable combined ratio is meaningfully higher than 85 — call it the low-to-mid-90s — which is the crux of the valuation.

Returns. ROE: −2.7% (2022) → −0.6% (2023) → 8.8% (2024) → 17.6% (2025); return on capital ~15.7% in 2025; ROA ~8.9%. Management’s headline “44% adjusted-net-income return on capital” and “48.4% net-income ROE” (Q1-26 LTM) are peak-plus-one-time figures — useful for showing the franchise can earn spectacular returns at the top of the cycle, useless as a forward anchor. The honest normalized ROE for this franchise is ~12–14% (mid-90s auto/low-90s home combined ratios plus rising NII), with upside if the growth pivot and expense reductions stick.

Revenue/margins/composition. Revenue $67.7B (+6%); net investment income $3.45B (+11.5%) and structurally rising; underwriting income swung from −$2.2B (2023) to +$8.5B (2025). Gross margin is not a meaningful concept for an insurer (ROIC reports it as 100%); the combined ratio is the operating-margin analog.

Cash flow and earnings quality. Operating cash flow is strong and tracks earnings (per-share operating cash flow ~$38 in 2025), and is structurally positive because premiums are collected before losses are paid (the float). The earnings-quality caveats are: (1) $1.6B of 2025 net income was one-time divestiture gains, not operating; (2) the $1.8B favorable reserve release is real cash-backed profit but is a non-repeating tailwind from over-reserving the 2023–2024 accident years; and (3) net realized investment losses (−$168M in 2025) and the ~12% performance-based (private-equity/LP) portfolio introduce mark-to-market and reporting-lag noise. Adjusted net income (which strips realized gains/losses and one-times) is the cleaner run-rate — ~$10.65/diluted share in Q1-26, though even that benefits from peak margins and reserve releases.

Balance sheet — fortress. Total equity $30.6B (+43% YoY, on retained earnings plus an AOCI recovery as bond prices rose); preferred $2.0B; common book ~$28.6B (~$110–120/share; tangible ~$95/share). Total debt only $7.49B, debt/capital ~10% — among the most conservative in the cohort. Investments $83.2B, 71% fixed income (top-quartile 5-year fixed-income returns per management), 12% performance-based. Net reserves $33.1B. The 1-in-100 catastrophe PML is capped at ~$3.1B net via a comprehensive nationwide reinsurance program (cost $1.23B in 2025). A-rated, liquid, and over-capitalized relative to its risk — $7.5B of deployable holding-company assets and statutory dividend capacity of ~$8B.

Note on a data discrepancy: one aggregator reports book value per share at ~$237; that figure is erroneous. The 10-K shows total shareholders’ equity of $30.6B, of which ~$28.6B is common (ex-$2.0B preferred), or ~$110–120 per ~260M shares — the basis used throughout this memo and consistent with the ~1.85× price-to-book.

Verdict: economics that are genuinely good and genuinely cyclical. The franchise compounds book value at a mid-teens-plus through-cycle ROE with a fortress balance sheet and rising investment income — but current margins are above mid-cycle and the headline returns are inflated by one-time gains and reserve releases. Do the economics improve with scale? Yes — scale lowers the expense and reinsurance ratios and grows the float — but the regulator and the capital cycle cap how much of that scale benefit reaches the bottom line over time.

7. Capital Allocation

Allstate’s capital allocation is above average — disciplined, return-focused, and heavily weighted to shareholder return, with a credible (if imperfect) M&A record.

Shareholder returns — the headline strength. Since 1995 Allstate has repurchased 799M shares for $44.5B, reducing the share count ~71%. The dividend was raised to $4.00/share in 2025 (from $3.68 in 2024, $3.56 in 2023) — a low ~10–22% payout that leaves ample room. In February 2026 the board authorized a new 24-month $4.0B buyback (after completing the prior $1.5B program), equal to ~7% of shares and ~40% of holding-company assets, and management says it has been accelerating the pace. Q1-26 returned $881M to shareholders. This is the core of the ownership case: at a ~$54B market cap, a $4B buyback plus a ~2% dividend is a ~9–10% capital-return yield, funded out of peak earnings and excess capital.

M&A — a mixed-to-good record. The two defining deals: SquareTrade (2017, product protection) — a clear success; revenue has grown ~8× and it earns ~$175M ANI on the Allstate brand and retail distribution. National General (2021, ~$4B) — built the independent-agent platform and non-standard auto presence; strategically sound, integration broadly complete. The 2025 divestitures of Health & Benefits ($1.9B EVB to Standard, $1.23B Group Health to Nationwide; $1.6B combined gain) were sensible portfolio pruning at good prices, redeploying capital from sub-scale, non-core businesses into the core P&C franchise and buybacks. The pattern — buy capability/distribution that leverages the brand, sell sub-scale non-core, return the rest — is rational and Greenwald-consistent (only acquire where “our ownership makes the business better,” in Wilson’s words).

Reinvestment in the core. ~$3B of economic capital deployed over three years to support premium growth; continued investment in the technology ecosystem and Arity; and active management of the investment portfolio (notably doubling equity exposure to ~12% in late-2025/early-2026 — a more aggressive, dynamic asset-allocation posture than most peers, which adds return but also volatility and is worth watching).

Incentives — reasonably aligned, with one gap. The annual cash incentive runs the property-liability result (70% of the market-facing roll-up) through a Profitable Growth Matrix of Combined Ratio × Items-in-Force growth — i.e., it explicitly pays for profitable growth, not growth at any cost, which is the right design for the current pivot — plus a 30% Performance Net Income gate. The long-term PSU plan pays on Average Performance-Net-Income Return on Equity (60%) and Relative TSR (40%) — a genuine return-on-equity metric and a market-relative metric, both appropriate. The gap: there is no standalone ROIC metric (ROE can be gamed with leverage/buybacks, though Allstate’s low leverage mutes that concern), and the combined ratio sits only in the annual plan, not the long-term plan. Say-on-pay passed with >95% support. CEO Tom Wilson earned $22.9M in 2025.

Governance demerits. Wilson has been CEO since 2007 and holds the combined Chair + President + CEO roles (offset by an independent lead director); insider/officer-director ownership is low at ~1.55%; and there is no evidence of open-market insider buying — recent Form 4 activity is the routine grant/option-exercise/tax-withholding/sell pattern (codes A/M/F/S), with no conviction P-code purchases. None of this is disqualifying for a mature mega-cap, but it is a mild negative on alignment and a yellow flag on long-tenure entrenchment/succession.

Verdict: above-average capital allocation — elite, sustained capital return; a sound, brand-leveraging M&A philosophy with a real success (SquareTrade) and disciplined pruning (H&B); and incentives that mostly reward profitable growth and ROE. Knocked down half a notch by the missing ROIC metric, the ~1.55%/no-buys insider picture, and a 19-year combined Chair/CEO.

8. Changes and Headwinds — Last Two Years

Strategic / portfolio.

• Exited Health & Benefits (2025). Sold Employer Voluntary Benefits to The Standard ($1.9B, closed Apr 1, 2025; $888M pre-tax gain) and Group Health to Nationwide ($1.23B, closed Jul 1, 2025; $715M gain), retaining only individual health as a non-reportable “all other.” A clean strategic simplification into a P&C-plus-Protection-Services pure-play — and the source of $1.6B of 2025’s flattering one-time gains.
• Segment reorganization (2025) into Allstate Protection / Protection Services / Run-off P-L / Corporate.
• Transformative Growth maturation. Expense ratio down to 21.4% (from 24.5% in 2021), ASC affordable/simple/connected products now in 40+ states for auto, 36+ for home, and Custom360 for independent agents in 40 states. The AI build (“ALLIE,” agentic AI) is the next leg.

Operating inflection.

• The underwriting recovery completed — PL combined ratio 104.5 (2023) → 94.3 (2024) → 85.2 (2025); ROE back to 17.6%.
• Growth pivot — PIF turned positive (+2.5% total in Q1-26) after years of intentional shrinkage; rate increases slowed to roughly neutral.
• Net investment income structurally higher (+11.5% in 2025) and a more aggressive equity allocation (doubled to ~12%).
• New nationwide reinsurance program disclosure (Q1-26) reducing cat-tail capital requirements and earnings volatility.

Capital actions. Dividend raised to $4.00; new $4.0B buyback (Feb 2026); buyback pace accelerating.

Headwinds / watch-items.

• Catastrophe volatility — cat losses have run $5.0–5.6B in three of the last four years; May 2026 alone brought $289M of cat losses (the proximate cause, with the KBW downgrade, of the recent ~2% pullback). Climate/severe-convective-storm frequency is a structural homeowners headwind, partly offset by reinsurance and rate.
• Regulatory friction in California (paused growth, awaiting intervenor reform), Florida (no new homeowners/condo business), and New York (upside if litigation reform passes — but not in Allstate’s control).
• Margin normalization — the inevitable reversion from an 89.5% auto underlying CR toward the mid-90s target as rate slows and (eventually) is cut, and as favorable reserve development fades.
• Competitive intensity — Progressive/GEICO advertising and cost-advantage pressure on auto share and an advertising “arms race” management is consciously trying not to over-feed.
• Sell-side caution — KBW downgraded to Market Perform on 8 Jun 2026 (PT $242), reflecting the peak-margin/peak-multiple concern at the center of this memo.

Verdict: net thesis-neutral-to-modestly-positive on strategy (cleaner portfolio, real operating inflection, strong capital return), but the headwinds — cat volatility, regulatory friction, and above all the coming margin normalization — are precisely what makes the price the live question rather than the business.

9. Risk Analysis (Risk Matrix)

Net risk read: the risks are overwhelmingly to earnings/margin (cyclical, #1–#5), not to solvency (#10 remote). The single most important is #1 — the market is paying a full price on peak margins, so the downside scenario is a multiple-plus-earnings de-rate, not a wipeout. There is essentially no risk of catastrophic permanent capital loss from the franchise itself.

10. Valuation Discussion (Embedded Expectations)

Where the multiples sit (own history). The valuation tells, cleaned of the GAAP-EPS distortion:

• P/E ~4.8× trailing — 1.6th percentile. Ignore as a level. TTM GAAP EPS (~$45.77) is inflated by $1.6B divestiture gains, an $1.8B reserve release, and peak underwriting margins. A 4.8× P/E does not mean “cheap”; it means “peak-plus-one-time E.”
• P/B ~1.85× — 77th percentile. The cleanest tell. Above the stock’s median but not at an extreme.
• P/S ~0.87× — 99.7th percentile. Richest-ever on sales — but sales have been inflated 38% in four years by rate, so high P/S partly reflects that premiums grew faster than the multiple’s denominator “should.” Still, it signals a full price.
• Composite ~59.5th percentile — middle of its own range, and notably the least stretched of the big-four P&C names (vs. TRV composite/P-B in the 90s, CB P/B 89th, PGR at its own richest-ever 3–4× book). On a relative own-history basis, Allstate is the cheapest of the quality personal-lines/specialty cohort.

Embedded-expectations / scenario analysis. The right anchor is normalized earnings and price-to-book, not trailing P/E. Common book is ~$115/share. Normalized through-cycle ROE for this franchise is ~12–14% (mid-90s auto, low-90s home, rising NII), implying normalized EPS of ~$15–19 and normalized adjusted ROE possibly higher in the near term while margins remain above mid-cycle.

What the current ~$221 price embeds. At ~1.85× book and ~12–13× a normalized ~$17, the market is underwriting the base case with a lean toward the bull — i.e., that Allstate sustains a low-to-mid-90s combined ratio and re-accelerates profitable unit growth while returning ~9–10% of its cap annually. It is not pricing the bear (a clean reversion to a 96–98 CR with stalled growth would justify ~$165–185). The market is correctly pricing the franchise quality, the capital return, and the rising NII; it is arguably under-pricing the cyclicality (paying near-peak P/S on near-peak margins) and over-trusting the durability of an 89.5% auto underlying CR that management itself says it will spend down.

Cross-checks. EV ~$58.4B; EV/sales 0.86× (low, as always for an insurer). On peer relative value, Allstate trades at a deserved discount to Progressive (lower growth, lower ROE, cost-disadvantaged auto) and roughly in line with Travelers/Chubb on book — but at a less-stretched own-history percentile than any of them, which is the most interesting valuation fact in the name.

Verdict (no target, no recommendation): fairly-to-fully valued on normalized economics, with the multiple embedding a successful margin-for-growth pivot. The asymmetry is roughly balanced-to-slightly-unfavorable at $221: ~10–15% downside to a clean cyclical-reversion bear, ~15–30% upside if the growth pivot re-rates the multiple — with the ~9–10% annual capital-return yield doing much of the work in the base case. (The directional zone and the position are stated only in Claude’s Take.)

11. Variant Perception

Consensus. “High-quality personal-lines insurer that nailed the hard-market recovery; record margins and returns; aggressive buyback; reasonable price near highs.” Sell-side is broadly constructive but cooling at the margin (KBW’s June downgrade to Market Perform, PT $242, captures the “great results, full price, peak margins” caution). The factor model shows a low-beta (0.66 market / 0.31 raw), high-Sharpe (1.09 over 3y) quality / low-volatility / dividend-yield / value name near its relative-strength peak — i.e., a crowded, well-owned defensive-quality compounder, not a contested or hated stock.

The strongest bull case. Allstate has structurally improved: the expense ratio is down ~3 points (Transformative Growth), the portfolio is cleaner (H&B gone) and earning more (NII +11%), the homeowners franchise is taking profitable share where rivals won’t, and management is pivoting from rate-and-shrink to profitable growth with the balance sheet and buyback to fund it. If PIF re-accelerates to 4–5% while the combined ratio holds at target, the market re-rates a ~1.85× book stock toward 2.0–2.2× and book value compounds at mid-teens — a 20–30%+ total return with downside protection from the defensive factor profile and the ~9–10% capital-return yield. The “cheap on a 4.8× P/E” headline, while distorted, isn’t entirely wrong: even on normalized ~$17 EPS, ~13× for a mid-teens-ROE compounder returning ~10% of cap a year is not demanding.

The strongest bear case. Current earnings are a cyclical and one-time peak. The 89.5% auto underlying CR is ~5 points below management’s own target; $1.6B of 2025 income was divestiture gains; $1.8B was a reserve release that won’t repeat. As rate slows to neutral and (in adequate states) turns to cuts, and as the favorable reserve development fades, the combined ratio reverts toward the mid-to-high-90s and EPS falls 25–35% from the current run-rate. Meanwhile the market is paying the 99.7th-percentile P/S and 77th-percentile P/B — i.e., a full multiple on those peak earnings. Layer in the structural auto cost disadvantage vs. Progressive (so the “buy growth with margin” pivot may simply hand the windfall to customers and still lose auto share) and the cat/regulatory overhang, and you have a stock priced for continuation of a peak that the company is actively planning to spend down.

The 3–5 assumptions that matter most:

1. Sustainable combined ratio — does auto settle at the mid-90s target (bear-ish for current EPS) or can structural expense gains hold it lower (bull)? Most important.
2. Profitable unit growth — can PIF grow 3–5% without sacrificing target margins, against Progressive’s cost edge?
3. Reserve adequacy of 2025–2026 accident years — were the 2023/2024 releases skill or luck; will 2025 develop favorably or adversely?
4. NII trajectory — how much does the reinvestment-yield tailwind and the larger equity allocation add (and at what added volatility)?
5. Regulatory unlocks — does NY/CA reform open growth, or stay stuck?

What would falsify each side. Bull falsified if, over the next 2–4 quarters, the combined ratio drifts above target and PIF growth stalls — peak confirmed, de-rate follows. Bear falsified if Allstate posts several quarters of 4%+ PIF growth at target combined ratios with continued homeowners share gains — proving the structural step-change and justifying multiple expansion. The factor read (crowded, near-peak, defensive-quality) says consensus is comfortably long the quality and the capital return and is under-hedged to the cyclicality — the place a variant view most plausibly lives is in the margin-normalization timing.

Verdict: consensus is right about the franchise and the capital return and is likely too sanguine about the durability of peak margins — the variant edge is recognizing that the cheap-looking P/E is peak-plus-one-time, and sizing the position to own the compounding while leaving room to add if/when the inevitable margin normalization gives a better entry.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the true sustainable auto combined ratio once rate goes neutral-to-negative and structural expense gains are netted against competitive give-backs — 92? 94? 96? This single number drives 25%+ of normalized EPS.
2. Were the 2023–2024 reserve releases repeatable skill or one-time over-reserving? Will 2025/2026 accident years develop favorably or adversely?
3. Can Allstate grow auto units profitably against Progressive’s cost advantage, or does “buying growth with margin” simply normalize returns without winning share?
4. How much incremental NII (and how much added P&L volatility) comes from the doubled, ~12% equity allocation and higher reinvestment yields?
5. Do New York and California regulatory reforms actually pass, and how large is the resulting growth unlock?
6. Succession — Wilson is in year 19 as CEO; what is the plan, and does the combined Chair/CEO structure persist?
7. What is the run-rate cat load as severe-convective-storm frequency rises — is the reinsurance program (cost $1.23B and rising) keeping pace with the underlying trend?

14. What Must Be True

For the bull case (own it / add):

• The combined ratio settles in the low-to-mid-90s, not high-90s — structural expense reductions and pricing sophistication hold margins near target even as rate slows.
• PIF grows 3–5%+ profitably — homeowners share gains continue, auto re-accelerates without margin collapse, and Protection Services compounds low-teens.
• NII keeps rising as the portfolio reinvests at higher yields, adding a quiet earnings tailwind.
• The $4B buyback shrinks the share count ~7% at a reasonable price, and book value compounds at mid-teens.
• Falsification test: if, over the next 2–4 quarters, the combined ratio drifts above the mid-90s target AND total PIF growth stalls below ~2%, the bull case is broken — current earnings were peak, and the stock should de-rate toward ~$165–185.

For the bear case (avoid here / trim):

• Current ~85–86 combined ratios are an unsustainable peak; reversion to the mid-to-high-90s is mechanical as rate normalizes and reserve releases fade.
• The market is paying 99.7th-percentile P/S and 77th-percentile P/B on those peak earnings, leaving no margin of safety against a 25–35% EPS air-pocket.
• The auto cost disadvantage vs. Progressive caps profitable share gains, so the growth pivot disappoints.
• Falsification test: if Allstate posts several consecutive quarters of 4%+ profitable PIF growth at or below target combined ratios with continued homeowners share gains, the bear thesis (peak-and-fade) is wrong — the franchise has structurally re-rated and deserves multiple expansion toward 2.0–2.2× book.

Synthesis: the bull and bear hinge on the same two variables — sustainable combined ratio and profitable unit growth — observable quarterly. That makes this a monitorable thesis: you can own the quality and the ~9–10% capital-return yield today, and let the next several prints tell you whether to add (growth pivot working) or trim (peak fading). The price ($221, near highs, full-but-not-extreme multiple) does not force the decision either way, which is why the labeled call is HOLD / accumulate-on-weakness rather than a high-conviction buy or sell.

15. Source Appendix

See Appendix B for the full source list. Primary sources: Allstate FY2025 Form 10-K (filed 2026-02-20); DEF 14A proxy (filed 2026-04-10); Q1-2026 earnings call transcript (2026-04-30); SEC EDGAR filing corpus (CIK 0000899051). Quantitative data: public statements/ratios/enterprise value, valuation-percentile and price-history services, and a public factor model. Peer comparisons drawn from the public filings of Progressive (PGR), Travelers (TRV), and Chubb (CB). All non-obvious facts cited inline with form/section references.

APPENDIX A — Standard Diligence Questionnaire

Supplemental to the research memo. Fact / Interpretation / Assumption labels applied where it matters.

General

What thoughtful questions have other investors asked about this company? The recurring institutional questions (visible in the Q1-26 call) are: (1) How sustainable are these margins? — Josh Shanker (BofA) pressed directly on the ~$840M favorable auto reserve release and whether margins are deteriorating year-over-year off an “incredible” base; management conceded margins will come down (“they have to deteriorate at some point”). (2) How do you grow profitably with lower prices? — the BMO question on leaning into pricing, answered with the “Rubik’s Cube” of competitive levers beyond price. (3) Holdco capital prioritization (Barclays) — buyback pace vs. M&A vs. portfolio. (4) AI / expense competitiveness vs. peers who are cutting workforce. (5) Asset allocation — the doubling of equities to ~12%. The through-line: investors trust the franchise and are probing the durability of peak margins and the quality of the growth pivot — the exact crux of the debate.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Cyclical high (Fact + Interpretation). PL combined ratio 85.2 (2025) vs a mid-90s target and a 106.6 trough (2022); auto underlying CR 89.5% in Q1-26 vs target. Plus one-time boosts ($1.6B divestiture gains, $1.8B reserve release). Current earnings are above mid-cycle.

Driven by the external environment or internal actions? Both. Externally: the post-2022 industry-wide hard market and benign-ish recent catastrophe/loss-cost trends. Internally: ~30% cumulative auto rate increases, expense-ratio reduction (24.5→21.4), and portfolio repositioning. The recovery was largely self-help (rate); the level of current margins is cycle-aided.

How stable are revenues? Premium revenue is highly recurring (annual renewals, high retention), but the level swings with the rate cycle — revenue grew ~10%/yr 2020–2025 almost entirely on price. Net investment income (~$3.4B) is stable-to-rising. Realized investment gains/losses are volatile.

Outlook for products/services? Auto insurance demand is non-discretionary and grows with vehicles/inflation; homeowners with home values and replacement cost. Protection Services (SquareTrade) grows with retail attach rates. Structural unit growth depends on winning share, not market expansion.

How big will this market be? U.S. personal P&C is a mature, ~$400B+, low-single-digit-real-growth domestic market (auto + home); Allstate is ~US/Canada only. Growth is share-driven, not market-driven. (Fact: domestic, mature.)

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Auto: persistently intense (Progressive/GEICO direct-cost and advertising pressure). Homeowners: less competitive (rivals retrenching from cat risk) — Allstate’s relative opportunity. (Interpretation, transcript-supported.)

How profitable is the business (ROIC, ROE)? ROE 17.6% (2025, peak); return on capital ~15.7%; normalized through-cycle ROE ~12–14% (Assumption). For an insurer, ROE/ROIC are the right metrics; “gross margin” is not meaningful (the combined ratio is the operating-margin analog: 85.2 in 2025).

How profitable is the industry — competitors, barriers? A scale oligopoly (top-5 dominate auto); barriers = scale economies (brand, claims, data, reinsurance buying), regulatory licensing, and capital. Returns are mean-reverted by the capital cycle and rate regulators — attractive at the top, loss-making at the bottom.

Can the business be easily understood? Reasonably — premiums in, losses + expenses out (combined ratio), plus investment income on the float. The complexity is in reserving, catastrophe modeling, and the investment portfolio (incl. ~12% illiquid performance-based LPs).

Undermined by foreign low-cost labor? No — domestically regulated, service/claims-local. AI/automation (not offshoring) is the cost lever.

Do brands matter? Yes, but not decisively. The Allstate brand (“You’re in good hands,” “Mayhem”) supports retention and bundling and lowers acquisition cost, but cannot overcome a ~15% price gap in shoppable auto. (Interpretation.)

Nature of competition? Price, advertising, distribution breadth, claims service, and increasingly pricing-data sophistication (telematics/AI). Allstate competes on a “broad set of levers,” not lowest price.

Customers’ switching costs? Low in auto (minutes to shop/switch), moderate when bundled auto+home (inconvenience of moving both). Retention is high but not contractually locked.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The Allstate brand and agency/distribution network are internally generated and not capitalized; the float’s economic value exceeds its accounting carry. (Interpretation.)

Off-balance-sheet liabilities? The principal “hidden” exposures are catastrophe tail risk (capped at ~$3.1B net 1-in-100 via reinsurance) and loss-reserve uncertainty (net reserves $33.1B; A&E run-off ~$1.0B+). NFIP flood is fully indemnified by FEMA (Allstate acts as agent). No unusual operating-lease or pension red flags noted.

How conservative is the accounting? Reasonably — recent accident years (2023/2024) developed favorably, suggesting initial reserving was conservative; centralized reserving is separated from pricing actuaries with external actuarial review. Watch-item: the larger, lagged, illiquid performance-based investment book and realized-gain volatility.

How CapEx-hungry? Capital-light operationally (no heavy PP&E); “capital intensity” is regulatory capital/statutory surplus to support premium and catastrophe risk, plus technology investment. Free-cash conversion is high.

Capital Allocation & Management

How much FCF, and how is it used? Strong, premium-funded operating cash flow (~$38/share in 2025). Uses, in management’s stated priority: organic growth (~$3B economic capital over 3 yrs), strengthening existing businesses (technology, portfolio), selective growth M&A, and shareholder return (dividends + buybacks) — the residual and largest bucket.

Significant acquisitions recently? SquareTrade (2017, success, ~8× revenue growth); National General (2021, ~$4B, independent-agent platform). Recent activity is the opposite — divesting Health & Benefits ($3.1B proceeds, $1.6B gains, 2025).

Buying back shares? Aggressively — 71% share-count reduction since 1995; new $4.0B (24-month, ~7% of shares) authorized Feb-2026, pace accelerating.

Issuing shares to insiders? Routine equity comp (PSUs/options); no unusual dilution — net share count falling. Form 4 activity is grants/exercises/tax-withholding/sales (codes A/M/F/S), no open-market purchases.

Compensation policy? CEO Wilson $22.9M (2025); >90% at-risk. Annual incentive on a Combined-Ratio × Items-in-Force-growth matrix (70% weight) + Performance Net Income (30%); long-term PSUs on net-income ROE (60%) + relative TSR (40%). Say-on-pay >95%. Gap: no standalone ROIC metric; combined ratio only in the annual (not long-term) plan.

Motivations of management? Reasonably aligned to profitable growth and ROE via the incentive design, but ~1.55% insider ownership and no open-market buying temper the “owner-operator” alignment. Wilson is in year 19 — succession is an open governance question.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — a standard U.S. C-corp common stock (NYSE: ALL); 1099 dividends; not an ADR/MLP/K-1.

Dividend policy? Quarterly cash dividend, $4.00/share annualized (2025), low payout (~10–22% of earnings), regularly raised; plus three series of preferred stock ($2.05B liquidation preference).

How profitable is the business? Peak-cycle very profitable (17.6% ROE, 85.2 combined ratio); normalized ~12–14% ROE.

Net income diverging from cash from operations? Operating cash flow tracks earnings closely (float-funded). The 2025 divergence to watch is quality: ~$1.6B of net income was non-operating divestiture gains and ~$1.8B was a reserve release — both real/cash-backed but non-recurring. Adjusted net income is the cleaner run-rate.

Risks & Downside

What would cause the stock to decline? Margin normalization (combined ratio reverting to/above the mid-90s as rate slows and reserve releases fade); a heavy catastrophe year; loss-cost-inflation re-acceleration; auto share loss to Progressive; regulatory rate suppression; or simple multiple compression from a full (P/S 99.7th pctile) starting point.

Risk of a catastrophic loss? Low at the enterprise level — A-rated, ~10% debt/capital, reinsured cat tail (~$3.1B net 1-in-100 PML), diversified $83B portfolio. A single event impairing solvency is remote.

Chance of a total loss? Negligible. This is an earnings-cyclicality and valuation story, not a balance-sheet-risk story. The realistic downside is a ~10–35% drawdown in a peak-fade scenario, not permanent capital impairment.

Recent News & Events

Has the business environment changed recently? Yes, favorably on operations: the underwriting recovery completed (CR 85.2), PIF growth turned positive (+2.5%), NII rising (+11%), and the portfolio was simplified (H&B exit). The pivot from rate-and-shrink to profitable-growth is the key change. The competitive and regulatory environment is broadly stable (intense auto competition; CA/NY/FL friction).

Significant acquisitions? Net divestitures, not acquisitions (Health & Benefits sold in 2025).

Change in accounting policies? Segment reorganization in 2025 (four reportable segments); no material accounting-principle change flagged.

Recent changes — new markets, facilities, management? Product expansion (ASC affordable/simple/connected auto in 45 states, home in 36; Custom360 for independent agents in 40 states); the “ALLIE” agentic-AI build; doubled equity allocation (~12%); new $4B buyback. News-flow events: KBW downgrade to Market Perform (8 Jun 2026, PT $242) and May-2026 catastrophe losses of $289M — the proximate cause of the recent ~2% pullback from the all-time high.

APPENDIX B — Source Appendix

Report date: 2026-06-20. Primary sources first. All figures reconciled to filings where possible; third-party aggregated data labeled as such.

Primary — SEC / company filings (CIK 0000899051)

1. Form 10-K, FY2025 — filed 2026-02-20 (all-20251231.htm). Segment revenues/premiums by line; combined ratios (PL 85.2; auto 85.0; home 84.4) and history (2021–2025); catastrophe losses ($5.0B, 8.6 pts); prior-year reserve development ($1.81B favorable, 3.1 pts); PIF (auto 25,504k; home 7,697k); average premiums; net investment income ($3.45B); investment portfolio ($83.2B, 71% fixed income, 12% performance-based); equity ($30.6B), preferred ($2.0B), debt ($7.49B), debt maturities; Health & Benefits divestiture (Note 4: EVB to Standard $1.9B/$888M gain closed 4/1/25; Group Health to Nationwide $1.23B/$715M gain closed 7/1/25); nationwide cat reinsurance program ($9.51B xs $1.0B; cost $1.23B; 1-in-100 PML ~$3.1B net); dividends declared ($4.00); buybacks (6M shares/$1.23B in 2025; 71.1% share reduction since 1995); holdco deployable assets ($7.5B); statutory dividend capacity (~$8B).
2. Form 10-K, FY2021–FY2024 — filed 2022-02-18, 2023-02-16, 2024-02-21, 2025-02-24. Multi-year combined ratios, cat losses, PIF, and reserve-development history.
3. DEF 14A proxy — filed 2026-04-10 (all-20260410.htm). CEO Tom Wilson total comp ($22,920,898 FY2025; CEO since 2007; Chair+President+CEO; independent lead director Hume); annual incentive design (Profitable Growth Matrix = Combined Ratio × Items-in-Force growth, 70%; Performance Net Income, 30%; paid 127.2% of target); long-term PSU metrics (Avg Performance-NI ROE 60% + Relative TSR 40%; no ROIC); say-on-pay >95%; director/officer beneficial ownership ~1.55%.
4. Form 4 filings (2024–2026 sample) — EDGAR. Recent transactions are routine grants/option-exercises/tax-withholding/sales (codes A/M/F/S); no open-market (code P) purchases observed in the sample.
5. Form 8-K filings (2025–2026) — Health & Benefits divestiture closings; quarterly earnings releases; buyback authorizations; monthly catastrophe-loss disclosures (May 2026: $289M).
6. Q1-2026 earnings call transcript — 2026-04-30 (via ROIC.ai). Revenue $16.9B (+3%); PL combined ratio 82.0 / underlying 80.3 (−2.8 pts); auto underlying CR 89.5 (vs mid-90s target); NII $938M (+9.8%); PIF +2.5%; adjusted NI $10.65/diluted share; new $4B buyback ($3.6B remaining, ~7% of shares); $881M returned in Q1; equity allocation doubled to ~12%; portfolio book value +24%/+$17B since Q1-24; SquareTrade ~$175M LTM ANI; Transformative Growth / ALLIE agentic AI; CA/NY/FL regulatory commentary; margin-for-growth pivot (“to the extent we can drive growth and give up some margin… improve shareholders’ valuation multiples”); 5/10-yr auto CR 94–95, home CR 92–93.5.

Quantitative data services (third-party aggregated; reconciled to filings)

7. ROIC.ai — income statement, balance sheet, profitability ratios (ROE, ROIC, margins), per-share data, enterprise value ($58.4B), valuation multiples. Multi-year (2020–2025) trends. Note: ROIC’s reported book-value-per-share (~$237) is erroneous; corrected to ~$110–120 common BVPS from the 10-K equity figure.
8. AZI (azitrading.com) — valuation_index own-history percentiles: P/E 1.6th (distorted — ignore), P/B 77th (~1.85×), P/S 99.7th (~0.87×), composite 59.5th; daily price/OHLCV CSV (split/dividend-adjusted, 1993–2026; beta 0.31); news feed (KBW downgrade 6/8 PT $242; May cat $289M; post-earnings −4.6%).
9. FactorsToday (factorstoday.com) — factor loadings (market beta 0.66; insurance industry 1.15; DividendYield +0.36, LowVolatility +0.29, Value +0.17, Growth −0.31); risk-adjusted track record (3-yr return +28.4% ann., Sharpe 1.09, max drawdown −14.1%; 1-yr +15.3%, max DD −11.5%); relative strength near peak; related/factor-similar peers (HIG closest, then TRV/CINF/CB/ACGL).

Peer / cross-read (public filings)

10. PGR (Progressive): ~3–4× book, ~40% comprehensive ROE at cycle peak, the auto cost/growth leader; Allstate’s primary competitor and the relative-value benchmark.
11. TRV (Travelers): ~1.7–2× book (P/B 93rd pctile), mid-teens ROE; commercial-weighted comparison.
12. CB (Chubb): ~1.6× book / ~1.6× tangible (P/B 89th pctile); specialty/commercial comparison.

Methodology notes

• No price target and no buy/sell appears in the analytical body or appendices; the single view is confined to the opening Take.
• GAAP P/E is distorted by 2025 divestiture gains, the reserve release, and peak underwriting margins; P/B and P/S percentiles are used as the honest valuation tells, and normalized-EPS / price-to-book scenarios anchor the valuation discussion.
• Insurance-appropriate metrics (combined ratio, ROE, book-value growth, NII, statutory surplus) substitute for generic gross-margin/FCF framing where the latter is not meaningful.
• All third-party aggregated data treated as a cross-check, with SEC filings authoritative for any material number.